PL3192874T3 - Oczyszczanie wirusa - Google Patents

Oczyszczanie wirusa

Info

Publication number
PL3192874T3
PL3192874T3 PL16002644T PL16002644T PL3192874T3 PL 3192874 T3 PL3192874 T3 PL 3192874T3 PL 16002644 T PL16002644 T PL 16002644T PL 16002644 T PL16002644 T PL 16002644T PL 3192874 T3 PL3192874 T3 PL 3192874T3
Authority
PL
Poland
Prior art keywords
virus purification
virus
purification
Prior art date
Application number
PL16002644T
Other languages
English (en)
Inventor
Richard Truran
Robert Buckley
Pippa Radcliffe
James Miskin
Kyri Mitrophanous
Original Assignee
Oxford Biomedica (Uk) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40940324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3192874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxford Biomedica (Uk) Limited filed Critical Oxford Biomedica (Uk) Limited
Publication of PL3192874T3 publication Critical patent/PL3192874T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091Purification or manufacturing processes for gene therapy compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Manufacturing & Machinery (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16002644T 2008-06-18 2009-06-18 Oczyszczanie wirusa PL3192874T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7368508P 2008-06-18 2008-06-18
EP09766124.3A EP2307551B1 (en) 2008-06-18 2009-06-18 Purification of retroviral vectors
PCT/GB2009/001527 WO2009153563A1 (en) 2008-06-18 2009-06-18 Virus purification
EP16002644.9A EP3192874B1 (en) 2008-06-18 2009-06-18 Virus purification

Publications (1)

Publication Number Publication Date
PL3192874T3 true PL3192874T3 (pl) 2020-06-29

Family

ID=40940324

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16002644T PL3192874T3 (pl) 2008-06-18 2009-06-18 Oczyszczanie wirusa
PL09766124T PL2307551T3 (pl) 2008-06-18 2009-06-18 Oczyszczanie wektorów retrowirusowych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL09766124T PL2307551T3 (pl) 2008-06-18 2009-06-18 Oczyszczanie wektorów retrowirusowych

Country Status (8)

Country Link
US (1) US9169491B2 (pl)
EP (2) EP3192874B1 (pl)
JP (2) JP5615271B2 (pl)
CN (2) CN102124115B (pl)
DK (2) DK3192874T3 (pl)
ES (2) ES2618851T3 (pl)
PL (2) PL3192874T3 (pl)
WO (1) WO2009153563A1 (pl)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094198A1 (en) 2010-01-28 2011-08-04 The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
EP2575894B1 (en) 2010-05-28 2015-02-25 Oxford Biomedica (UK) Ltd Delivery of lentiviral vectors to the brain
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
AU2012342355B2 (en) 2011-11-24 2017-10-12 Genethon Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
WO2013090409A1 (en) * 2011-12-12 2013-06-20 The Children's Hospital Of Philadelphia Large commercial scale lentiviral vector production system and vectors produced thereby
ES2765880T3 (es) 2012-01-09 2020-06-11 Sanofi Pasteur Biologics Llc Purificación del virus del herpes
CA2873775C (en) 2012-05-21 2021-04-20 Sanofi Pasteur Limited Herpesvirus compositions and related methods
DK2956477T4 (da) 2013-02-15 2024-04-15 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
EP2970920B1 (en) * 2013-03-15 2018-04-25 The Children's Hospital of Philadelphia Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
FR3010720B1 (fr) 2013-09-16 2017-08-11 Genethon Procede de production de virus enveloppes
FR3014901B1 (fr) * 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
CN104371982A (zh) * 2014-10-21 2015-02-25 武汉维诺赛生物技术有限公司 一种慢病毒的纯化方法
US10189880B2 (en) 2014-11-03 2019-01-29 Leiden University Medical Center T cell receptors directed against Bob1 and uses thereof
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
EP3268014B1 (en) 2015-03-10 2022-09-21 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
CN108603200B (zh) 2015-11-23 2022-08-19 诺华股份有限公司 优化的慢病毒转移载体及其用途
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
CN107043784A (zh) * 2016-02-05 2017-08-15 上海吉凯基因化学技术有限公司 一种慢病毒载体的制备方法
JP2019519250A (ja) 2016-05-10 2019-07-11 ユナイテッド ステイツ ガバメント アズ リプレゼンテッド バイ ザ デパートメント オブ ベテランズ アフェアーズUnited States Government As Represented By The Department Of Veterans Affairs Hiv−1感染と複製に必須な遺伝子を切断するcrispr/casの構築物のレンチウィルスによる送達
GB201614050D0 (en) * 2016-08-17 2016-09-28 Glaxosmithkline Ip Dev Ltd Method for purifying viral vectors
EP3714055A1 (en) 2017-11-21 2020-09-30 CRISPR Therapeutics AG Materials and methods for treatment of autosomal dominant retinitis pigmentosa
AU2018393050A1 (en) 2017-12-21 2020-06-18 Bayer Healthcare Llc Materials and methods for treatment of Usher Syndrome Type 2A
WO2019123430A1 (en) 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
FI3633040T3 (fi) 2017-12-22 2023-08-03 Oxford Biomedica Ltd Retrovirusvektori
EA202092069A1 (ru) * 2018-04-05 2021-03-12 Оксфорд Юниверсити Инновейшн Лимитед Композиции и способы лечения макулярной дистрофии
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11485956B2 (en) 2018-06-12 2022-11-01 Kbio Holdings Limited Virus and antigen purification and conjugation
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11529413B2 (en) 2018-06-12 2022-12-20 Kbio Holdings Limited Virus and antigen purification and conjugation
EP3836956A4 (en) * 2018-08-16 2022-05-18 Spacecraft Seven, LLC Production methods for viral vectors
KR20220034719A (ko) 2019-03-10 2022-03-18 시오 진 테라피스 인코포레이티드 파킨슨병을 치료하기 위한 유전자 요법 조성물 및 방법
US20220243224A1 (en) * 2019-04-15 2022-08-04 Children's Hospital Medical Center Viral vector manufacturing methods
JP2022551219A (ja) 2019-08-23 2022-12-08 ロンザ ウォーカーズヴィル,インコーポレーテッド レンチウイルスベクターの製造方法および構築物
TW202126284A (zh) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
CN115667533A (zh) 2020-02-13 2023-01-31 牛津生物医学(英国)有限公司 慢病毒载体的生产
JP2023516493A (ja) 2020-03-13 2023-04-19 オックスフォード バイオメディカ(ユーケー)リミテッド レンチウイルスベクター
CN116096430A (zh) 2020-04-27 2023-05-09 衣阿华大学研究基金会 用于治疗囊性纤维化的组合物和方法
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
WO2021262963A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
AU2021324776A1 (en) * 2020-08-13 2023-04-13 Tmunity Therapeutics Inc. Methods for producing clinical-grade lentiviral vector
CN112226418B (zh) * 2020-09-25 2022-07-08 阜外华中心血管病医院 重组腺相关病毒纯化方法
JP2023544184A (ja) * 2020-10-02 2023-10-20 ジェネラックス・コーポレイション 接着細胞からのウイルスのバイオリアクター生成
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
CN112899242A (zh) * 2021-02-03 2021-06-04 苏州博腾生物制药有限公司 慢病毒纯化工艺
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
WO2023074877A1 (ja) 2021-10-29 2023-05-04 Agc株式会社 細胞添加用組成物
WO2023085382A1 (ja) 2021-11-12 2023-05-19 Agc株式会社 ウイルスの精製方法
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
CN116240241A (zh) * 2022-12-30 2023-06-09 上海本导基因技术有限公司 重组慢病毒载体的纯化制备方法
JP2026504403A (ja) * 2023-02-01 2026-02-05 インテリウス・バイオセラピューティクス・インコーポレイテッド ウイルス粒子の濾過または精製のためのプロセス
WO2024259299A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Compositions and methods for identification of vhh antibodies that bind a target antigen
WO2025235738A1 (en) * 2024-05-08 2025-11-13 Interius Biotherapeutics, Inc. Methods of detecting residual dna in viral preparations

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78703A (en) 1985-05-10 1993-02-21 Benzon Alfred Method of producing extracellular enzymes, the enzymes produced thereby and compositions containing them; a hybrid plasmid and a dna fragment comprising dna encoding the enzymes; a microorganism harbouring the plasmid; and a method for removing nucleic acids from biological materials
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
ATE188740T1 (de) 1991-02-19 2000-01-15 Univ California Viruspartikel mit veraendertem wirtspektrum
US5512421A (en) 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
JPH09508017A (ja) * 1994-01-12 1997-08-19 ジェネティック セラピー,インコーポレイテッド レトロウイルスベクターの精製
PT751988E (pt) 1994-03-22 2000-05-31 Immune Response Corp Inc Producao e isolamento altamente eficientes de particulas virais
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998005635A1 (en) 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
WO1998017815A1 (en) 1996-10-17 1998-04-30 Oxford Biomedica (Uk) Limited Retroviral vectors
JP4492826B2 (ja) * 1996-11-20 2010-06-30 イントロジェン セラピューティクス,インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
ATE435297T1 (de) 1998-05-22 2009-07-15 Oxford Biomedica Ltd Retrovirales verabreichungssystem
GB9904905D0 (en) 1999-03-03 1999-04-28 Oxford Biomedica Ltd Cells
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0024550D0 (pl) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
AU2003220531B2 (en) * 2002-03-29 2007-11-01 Merck & Co., Inc. Large scale methods of producing adenovirus and adenovirus seed stocks
ES2285120T3 (es) 2002-05-14 2007-11-16 MERCK & CO., INC. Procedimientos de purificacion de adenovirus.
WO2004022761A1 (en) 2002-09-03 2004-03-18 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
US20050123514A1 (en) 2003-05-05 2005-06-09 Brian Davis Increased transduction using ABC transporter substrates and/or inhibitors
SE0302509D0 (sv) 2003-09-19 2003-09-19 Amersham Biosciences Ab Matrix for separation of polyethers and method of separation
CA2543189A1 (en) 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of parkinson's disease
CN1922308A (zh) * 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
DK2007883T3 (da) * 2006-04-20 2012-02-06 Wyeth Llc Rensningsfremgangsmåder til isolering af renset vesikulær stomatitis-virus fra cellekultur
WO2008065430A2 (en) * 2006-12-01 2008-06-05 Oxford Biomedica (Uk) Limited Promoter construct
US20100120665A1 (en) 2007-03-01 2010-05-13 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation
CA2705850C (en) * 2007-11-13 2016-07-19 Bio-Technology General (Israel) Ltd. Dilute filtration sterilization process for viscoelastic biopolymers

Also Published As

Publication number Publication date
CN103993040B (zh) 2018-02-13
JP6002720B2 (ja) 2016-10-05
CN102124115B (zh) 2020-03-03
PL2307551T3 (pl) 2017-07-31
EP3192874A1 (en) 2017-07-19
CN102124115A (zh) 2011-07-13
JP2011524887A (ja) 2011-09-08
ES2762864T3 (es) 2020-05-26
EP2307551A1 (en) 2011-04-13
EP3192874B1 (en) 2019-10-16
DK2307551T3 (en) 2017-03-20
WO2009153563A1 (en) 2009-12-23
EP2307551B1 (en) 2016-12-14
CN103993040A (zh) 2014-08-20
JP5615271B2 (ja) 2014-10-29
ES2618851T3 (es) 2017-06-22
DK3192874T3 (da) 2019-12-16
JP2014237661A (ja) 2014-12-18
US20090325284A1 (en) 2009-12-31
US9169491B2 (en) 2015-10-27

Similar Documents

Publication Publication Date Title
PL3192874T3 (pl) Oczyszczanie wirusa
GB0807424D0 (en) Virus
EP2334328A4 (en) METHOD FOR CLEANING VIRUSES
SG10201701988TA (en) Virus like particle purification
GB0822068D0 (en) Methods for virus design
GB0807607D0 (en) Catalyst
IL209017A0 (en) Structured coauthoring
SI2398785T1 (sl) Äśiĺ äśenje 1-(2-(2,4-dimetilfenilsulfanil)fenil)-piperazina
EP2234662A4 (en) FILTERED
SI2098275T1 (sl) Filter
GB0714578D0 (en) Viruses
PT2323610T (pt) Andarilho
IL212646A0 (en) Immunoglobulin purification
GB0808908D0 (en) Purification process
PL2379978T3 (pl) Dystrybutor płynów z symetrią obrotową
GB0912950D0 (en) Virus
GB0818228D0 (en) Purification process
GB0720624D0 (en) Viral Modification
GB0814668D0 (en) Filter
GB0901056D0 (en) Virus
GB0917623D0 (en) Nanoparticle purification
GB0811505D0 (en) Purification process
GB0821319D0 (en) Easy walker
GB0823560D0 (en) Virus
GB0803321D0 (en) Purification unit